Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Acq. announced
Consulting agrmnt
Director departure
Appointed director
CC transcript
Notes underwriting agrmnt
Inv. presentation
|
|
Sarepta Therapeutics, Inc. (SRPT)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/04/2019 |
8-K
| Investor presentation |
| 05/03/2018 |
8-K
| Investor presentation|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : May 3, 2018 Sarepta Therapeutics, Inc. Delaware 001-14895 93-0797222 215 First Street Suite 415 Cambridge, MA 02142 274-4000 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Exchang...",
"Sarepta Therapeutics Announces First Quarter 2018 Financial Results and Recent Corporate Developments — First quarter 2017 EXONDYS 51 ® total net revenues of $64.6 million — — Sarepta signs exclusive partnership and buy-out option with Myonexus Therapeutics; pipeline expands from 16 to 21 programs — — Company announces date of first R&D day, at which clinical data from gene therapy micro-dystrophin program will be announced — — Company receives negative trend vote following its CHMP oral explanation; will request re-examination and Scientific Advisory Group to be convened — CAMBRIDGE, Mass., May 3, 2018 — Sarepta Therapeutics, Inc. , a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, toda...",
"Oral Explanation Presentation Slides" |
|
| 10/01/2015 |
8-K
| Investor presentation |
|
|